menu
    • menu
    [{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Agreement","leadProduct":"Deutivacaftor","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Concert Pharmaceuticals","amount2":0.25,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.25,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Concert Pharmaceuticals \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Deutivacaftor","moa":"||CFTR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Vertex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Vanzacaftor","moa":"||CFTR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Granules","sponsorNew":"Vertex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vertex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Vanzacaftor","moa":"||CFTR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Granules","sponsorNew":"Vertex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vertex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Vanzacaftor","moa":"||CFTR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Granules","sponsorNew":"Vertex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vertex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"NHS England","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Agreement","leadProduct":"Deutivacaftor","moa":"||CFTR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Vertex Pharmaceuticals \/ NHS England","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ NHS England"}]

    Find Clinical Drug Pipeline Developments & Deals for Deutivacaftor

    Menu

    Deutivacaftor

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Vertex Pharmaceuticals

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Vertex Pharmaceuticals

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vanzacaftor,Deutivacaftor,Tezacaftor

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved FDF

                            Sponsor : NHS England

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Vertex Announces Broad Reimbursement Agreement With NHS England for ALYFTREK

                            Details : Vertex has reached a broad reimbursement agreement with NHS England for Alyftrek (vanzacaftor, tezacaftor, and deutivacaftor). It is being indicated for the treatment of Cystic Fibrosis.

                            Product Name : Alyftrek

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            July 14, 2025

                            Lead Product(s) : Vanzacaftor,Deutivacaftor,Tezacaftor

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved FDF

                            Sponsor : NHS England

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Vertex Pharmaceuticals

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Vertex Pharmaceuticals

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Deutivacaftor,Tezacaftor,Vanzacaftor

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Vertex Announces UK MHRA Approval of ALYFTREK for the Treatment of Cystic Fibrosis

                            Details : Alyftrek (deutivacaftor/tezacaftor/vanzacaftor), a once-daily next-in-class CFTR modulator, which is indicated for the treatment of cystic fibrosis.

                            Product Name : Alyftrek

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 07, 2025

                            Lead Product(s) : Deutivacaftor,Tezacaftor,Vanzacaftor

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Vertex Pharmaceuticals

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Vertex Pharmaceuticals

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vanzacaftor,Deutivacaftor,Tezacaftor

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Vertex Gets FDA Acceptance for Vanzacaftor/Tezacaftor/Deutivacaftor for Cystic Fibrosis

                            Details : VX-121/VX-661/VX-561 (vanzacaftor/tezacaftor/deutivacaftor) is a combination of three CFTR modulators. It is being evaluated in phase 3 clinial trials for the treatment of Cystic Fibrosis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 02, 2024

                            Lead Product(s) : Vanzacaftor,Deutivacaftor,Tezacaftor

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Vertex Pharmaceuticals

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Vertex Pharmaceuticals

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vanzacaftor,Deutivacaftor,Tezacaftor

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Vertex Announces Positive Results from Pivotal Trials for Cystic Fibrosis

                            Details : VX-121/VX-661/VX-561 (vanzacaftor/tezacaftor/deutivacaftor) is a combination of three CFTR modulators. It is being evaluated in phase 3 clinial trials for the treatment of Cystic Fibrosis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 05, 2024

                            Lead Product(s) : Vanzacaftor,Deutivacaftor,Tezacaftor

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Vertex Pharmaceuticals

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Vertex Pharmaceuticals

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vanzacaftor,Deutivacaftor,Tezacaftor

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Vertex Start Phase 3 Development Program for New Once-Daily Triple Combo Regimen

                            Details : The combination of VX-121/tezacaftor/VX-561 was first identified as having potential for increased efficacy based on its ability to drive higher levels of chloride transport compared to TRIKAFTA (elexacaftor/tezacaftor/ivacaftor /ivacaftor) in human bron...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 28, 2021

                            Lead Product(s) : Vanzacaftor,Deutivacaftor,Tezacaftor

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Concert Pharmaceuticals

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Concert Pharmaceuticals

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Deutivacaftor

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Sponsor : Vertex Pharmaceuticals

                            Deal Size : $250.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Concert Pharmaceuticals Announces Sale of VX-561 Milestones to Vertex for $32 Million

                            Details : VX-561 is an investigational cystic fibrosis transmembrane conductance regulator (CFTR) potentiator that has the potential to be used as part of future once-daily combination regimens of CFTR modulators that treat the underlying cause of cystic fibrosis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : $160.0 million

                            May 17, 2021

                            Lead Product(s) : Deutivacaftor

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Sponsor : Vertex Pharmaceuticals

                            Deal Size : $250.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth